ALIVUS
Glenmark Life Science
Each stock's 10,000-path forecast, rendered as light.
Glenmark Life Science (ALIVUS) Stock Analysis & Case Study
Is ALIVUS a good buy? The data-driven verdict.
on the numbers it mixed signals, a Downstox Snapshot Score of 50/100.
On the numbers, Glenmark Life Science (ALIVUS) mixed signals, a Downstox Snapshot Score of 50/100, weighing a 56% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
ALIVUS share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of ALIVUS history (13%/yr drift, 37%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| ALIVUS 2027 | ₹703 | ₹1,135 | ₹1,823 | +6% |
| ALIVUS 2028 | ₹605 | ₹1,204 | ₹2,387 | +12% |
| ALIVUS 2029 | ₹554 | ₹1,277 | ₹2,940 | +19% |
| ALIVUS 2030 | ₹510 | ₹1,352 | ₹3,544 | +26% |
| ALIVUS 2031 | ₹479 | ₹1,417 | ₹4,234 | +32% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability ALIVUS goes up, or doubles?
The bull case for ALIVUS
- Glenmark Life Science is part of the NSE universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹2,940.
The bear case & risks
- No model or past record guarantees future returns, treat this as one input, not a decision.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹554.
ALIVUS volatility & expected range, how bumpy is the ride?
Over the last 2.0 years ALIVUS compounded at 13%/year with annualized volatility of 37%. That volatility implies a 1-year 80% range of ₹703–₹1,823, the honest backbone behind any single price target.
ALIVUS price forecast, the full 60-month probability fan
ALIVUS price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds ALIVUS hits common targets within the simulated horizon?
Full multi-horizon detail on the ALIVUS price target & forecast page.
ALIVUS MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy ALIVUS with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.0% | 2.9× |
| ZerodhaCHEAPEST | 30.3% | 3.3× |
Compare every broker on the ALIVUS MTF page.
ALIVUS vs peers,sector comparison
About Glenmark Life Science: sector, index & market-cap context
Glenmark Life Science (ALIVUS) is an NSE-listed company.
How the ALIVUS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Glenmark Life Science's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
ALIVUS analysis, FAQs
Is Glenmark Life Science (ALIVUS) a good buy?
On the numbers, Glenmark Life Science (ALIVUS) mixed signals, a Downstox Snapshot Score of 50/100, weighing a 56% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is ALIVUS overvalued or undervalued?
Valuation ratios for ALIVUS are tracked live on Downstox.
What is the ALIVUS share price target for 2031?
ALIVUS's probability-weighted 2031 median target is ₹1,417, with an 80% range of ₹479–₹4,234 (10,000-path Monte-Carlo).
What is the probability ALIVUS doubles in 5 years?
The modelled probability of ALIVUS reaching ₹2,141 (2×) within 5 years is 32%.
What is the bull case for ALIVUS?
Glenmark Life Science is part of the NSE universe with live, tracked fundamentals on Downstox.
What are the risks in ALIVUS?
No model or past record guarantees future returns, treat this as one input, not a decision.